The SAVE Trial: Securing All IntraVenous Devices Effectively In Hospitals. A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$980,393.00
Summary
Going to hospital usually means having an IV drip in your hand or arm vein. Almost half of all IV drips fall out or fail because they are not well secured to the skin. This means patients miss out on treatment and have additional painful needlesticks to insert new devices. Serious infections can also occur. This study will find the best dressings to use on IV drips. Patients will have their drips glued in with medical superglue, or have one of two new dressings, compared with current usual care.
INTroducing A Care Bundle To Prevent Pressure Injury (the INTACT Trial)
Funder
National Health and Medical Research Council
Funding Amount
$1,093,250.00
Summary
In Australia, hospital acquired pressure injuries (i.e. bedsores) range from 7.4% – 17.4%. A care bundle is a structured group of interventions associated with improved patient outcomes. The aim of this 3-year cluster randomised controlled trial is to provide rigorous evidence regarding the effect of a patient centred pressure injury prevention care bundle on the development of pressure injuries in patients at risk of developing a hospital acquired pressure injury.
Intravascular Device Administration Sets: Replacement After Standard Versus Prolonged Use (The RSVP Trial)
Funder
National Health and Medical Research Council
Funding Amount
$1,611,239.00
Summary
Most hospital patients need an IV drip, a small plastic tube in a vein, often the hand/arm. 14 million/yr are used in Australia. IV drips are connected to plastic tubing through which fluid & medicine is given. IV tubing is needed for a week or more, but is only used for 3-4 days as it was thought this might prevent infection. It is now thought that IV tubing can be used for a week. This would save $1 billion/year & reduce nurses workload. The research will test the safety of this approach.
EPIGENETIC REPROGRAMMING OF MALIGNANT BREAST CANCER
Funder
National Health and Medical Research Council
Funding Amount
$863,268.00
Summary
Poorly differentiated breast cancers are aggressive tumors, frequently resistant to chemotherapy and associated with high morbidity. Herein we propose the engineering of more selective therapeutic agents able to target the genes involved in cancer initiation and resistance to treatment. We aim to correct and reprogram the cancer cell genome in state that is similar to normal, not tumorigenic cells. This work will generate novel forms of treatment for cancers that are presently not curable.